Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

Date publication

septembre 2017

Journal

The New England journal of medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier , Pr FEUGIER Pierre , Pr FORNECKER Luc-Matthieu , Pr CALLANAN Mary

Tous les auteurs :
Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28953447

Résumé

Mantle-cell lymphoma is generally incurable. Despite high rates of complete response after initial immunochemotherapy followed by autologous stem-cell transplantation, patients have relapses. We investigated whether rituximab maintenance therapy at a dose of 375 mg per square meter of body-surface area administered every 2 months for 3 years after transplantation would prolong the duration of response.

Mots clés

Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Cisplatin, administration & dosage, Combined Modality Therapy, Cytarabine, administration & dosage, Dexamethasone, administration & dosage, Female, Hematopoietic Stem Cell Transplantation, Humans, Immunologic Factors, administration & dosage, Lymphoma, Mantle-Cell, drug therapy, Maintenance Chemotherapy, Male, Middle Aged, Proportional Hazards Models, Rituximab, administration & dosage, Survival Analysis, Transplantation, Autologous

Référence

N. Engl. J. Med.. 2017 09;377(13):1250-1260